Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNotes PayablesOther Accumulated ExpensesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal Liabilities
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Universe Pharmaceuticals (UPC) Short term Debt (2021 - 2025)

Universe Pharmaceuticals' Short term Debt history spans 4 years, with the latest figure at $5.9 billion for Q3 2024.

  • For Q3 2024, Short term Debt rose 106726.27% year-over-year to $5.9 billion; the TTM value through Sep 2024 reached $5.9 billion, up 106726.27%, while the annual FY2024 figure was $5.9 billion, 106726.27% up from the prior year.
  • Short term Debt for Q3 2024 was $5.9 billion at Universe Pharmaceuticals, up from $5.5 million in the prior quarter.
  • Across five years, Short term Debt topped out at $5.9 billion in Q3 2024 and bottomed at $19723.0 in Q3 2021.
  • The 4-year median for Short term Debt is $4.4 million (2022), against an average of $1.5 billion.
  • The largest annual shift saw Short term Debt soared 62.24% in 2023 before it soared 106726.27% in 2024.
  • A 4-year view of Short term Debt shows it stood at $19723.0 in 2021, then surged by 17033.62% to $3.4 million in 2022, then skyrocketed by 62.24% to $5.5 million in 2023, then skyrocketed by 106726.27% to $5.9 billion in 2024.
  • Per Business Quant, the three most recent readings for UPC's Short term Debt are $5.9 billion (Q3 2024), $5.5 million (Q3 2023), and $3.4 million (Q3 2022).